[Analysis of efficacy and safety of BCMA chimeric antigen receptor T cells in the treatment of 5 patients with recurrent/refractory IgD multiple myeloma].

Autor: Jia YC; Department of Hematology, Myeloma & Lymphoma Center, Second Affiliated Hospital of Navy Medical University, Shanghai 200003, China., Wang XX; Department of Hematology, Myeloma & Lymphoma Center, Second Affiliated Hospital of Navy Medical University, Shanghai 200003, China., Qiang WT; Department of Hematology, Myeloma & Lymphoma Center, Second Affiliated Hospital of Navy Medical University, Shanghai 200003, China., Liu J; Department of Hematology, Myeloma & Lymphoma Center, Second Affiliated Hospital of Navy Medical University, Shanghai 200003, China., Guo P; Department of Hematology, Myeloma & Lymphoma Center, Second Affiliated Hospital of Navy Medical University, Shanghai 200003, China., Lu J; Department of Hematology, Myeloma & Lymphoma Center, Second Affiliated Hospital of Navy Medical University, Shanghai 200003, China., Fan XQ; Department of Hematology, Myeloma & Lymphoma Center, Second Affiliated Hospital of Navy Medical University, Shanghai 200003, China., He HY; Department of Hematology, Myeloma & Lymphoma Center, Second Affiliated Hospital of Navy Medical University, Shanghai 200003, China., Du J; Department of Hematology, Myeloma & Lymphoma Center, Second Affiliated Hospital of Navy Medical University, Shanghai 200003, China.
Jazyk: čínština
Zdroj: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi [Zhonghua Xue Ye Xue Za Zhi] 2023 Dec 14; Vol. 44 (12), pp. 1035-1037.
DOI: 10.3760/cma.j.issn.0253-2727.2023.12.012
Databáze: MEDLINE